Physician
LMW Healthcare INC.
LMW Healthcare INC. was paid $13.10M by Medicaid between Jan 2018 and Dec 2024, across 144 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoLMW HEALTHCARE INC.
WESTERLY, RI 02891
WESTERLY, RI 02891
33aNPI1447595368assigned 12/04/2012
33bProvider typeInternal Medicine Physician
28Total paid$13.10M
24GClaims349,423
24DCodes billed144
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Rhode Island
Rank by total paid#1 of 386
Median peer was paid$15K
This provider vs. median854×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WRINN, JACQUELINE controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,093 | $1.27M | |
| 2019 | 55,338 | $3.88M | |
| 2020 | 40,806 | $1.64M | |
| 2021 | 51,666 | $1.47M | |
| 2022 | 60,444 | $1.69M | |
| 2023 | 57,774 | $1.77M | |
| 2024incomplete | 42,302 | $1.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 10,133 | 8,076 | $2.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 5,233 | 4,132 | $1.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 11,354 | 8,991 | $1.72M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 20,754 | 16,107 | $445K |
| J3490 | Unclassified drugs | 3.3% | 14,908 | 5,145 | $433K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 3,966 | 3,197 | $422K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 5,280 | 4,216 | $337K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 7,779 | 2,069 | $337K |
| 36415 | Collection of venous blood by venipuncture | 2.3% | 19,689 | 15,212 | $306K |
| 80053 | Comprehensive metabolic panel | 2.2% | 10,432 | 8,253 | $286K |
| 82565 | 1.6% | 9,853 | 7,787 | $206K | |
| 82310 | 1.4% | 9,172 | 7,356 | $180K |
132 more codes
| 82947 | 1.3% | 9,059 | $172K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 2,649 | $168K |
| 84520 | 1.2% | 9,111 | $157K | |
| 84132 | 1.1% | 9,019 | $151K | |
| 82374 | 1.1% | 8,979 | $149K | |
| 82435 | 1.1% | 8,978 | $148K | |
| 84295 | 1.1% | 8,963 | $141K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 7,168 | $137K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 2,819 | $133K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,294 | $130K |
| 81001 | <1% | 5,635 | $128K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,321 | $117K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,810 | $116K |
| 82040 | <1% | 7,283 | $113K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,486 | $112K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,907 | $112K |
| 82247 | <1% | 6,929 | $105K | |
| 84460 | <1% | 7,258 | $104K | |
| 84450 | <1% | 7,264 | $103K | |
| 84155 | <1% | 6,925 | $99K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,445 | $95K |
| 84075 | <1% | 6,917 | $92K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 763 | $84K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 691 | $82K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,380 | $74K |
| 84484 | <1% | 3,540 | $73K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,864 | $68K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,351 | $67K |
| 80061 | Lipid panel | <1% | 3,410 | $58K |
| 88142 | <1% | 3,716 | $53K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,753 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,567 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,567 | $50K |
| G0378 | Hospital observation service, per hour | <1% | 1,607 | $50K |
| 83690 | <1% | 2,186 | $41K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,137 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,127 | $40K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,785 | $38K |
| 84439 | <1% | 2,360 | $38K | |
| 83735 | <1% | 2,129 | $37K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 241 | $37K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 416 | $37K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 387 | $37K |
| 85610 | <1% | 3,779 | $36K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 400 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,036 | $33K |
| 85027 | <1% | 2,308 | $32K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,705 | $28K |
| 82728 | <1% | 2,022 | $24K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 670 | $23K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,029 | $19K |
| 82607 | <1% | 1,352 | $19K | |
| 83550 | <1% | 2,259 | $19K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 455 | $18K |
| 80305 | <1% | 201 | $17K | |
| 84703 | <1% | 1,577 | $16K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 70 | $16K |
| 81003 | <1% | 1,394 | $16K | |
| 83540 | <1% | 2,285 | $15K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 192 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,855 | $14K |
| 83718 | <1% | 1,686 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,575 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 364 | $10K |
| 86140 | <1% | 829 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,733 | $6K |
| 83605 | <1% | 307 | $6K | |
| 86666 | <1% | 100 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 88 | $4K |
| 86618 | <1% | 262 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 98 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 24 | $3K |
| 85652 | <1% | 286 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 35 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 61 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 50 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 29 | $2K |
| 94664 | <1% | 281 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 49 | $2K |
| 87186 | <1% | 69 | $1K | |
| 82962 | <1% | 976 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 35 | $1K |
| 97162 | <1% | 29 | $1K | |
| 87469 | <1% | 12 | $1K | |
| 82746 | <1% | 65 | $926.08 | |
| 82248 | <1% | 237 | $905.28 | |
| 82570 | <1% | 111 | $790.90 | |
| 82465 | <1% | 1,696 | $650.08 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 318 | $597.90 |
| 86900 | <1% | 18 | $576.78 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 18 | $561.78 |
| 73562 | <1% | 16 | $542.30 | |
| 86038 | <1% | 31 | $451.23 | |
| 87070 | <1% | 112 | $425.28 | |
| 84478 | <1% | 1,698 | $383.50 | |
| 86803 | <1% | 41 | $381.64 | |
| 82784 | <1% | 15 | $301.83 | |
| 73560 | <1% | 21 | $218.52 | |
| 87480 | <1% | 14 | $210.65 | |
| 87510 | <1% | 14 | $210.65 | |
| 87660 | <1% | 14 | $210.65 | |
| 81002 | <1% | 33 | $202.76 | |
| 82042 | <1% | 37 | $194.90 | |
| 85007 | <1% | 31 | $146.16 | |
| 84550 | <1% | 13 | $69.10 | |
| 83880 | <1% | 13 | $64.84 | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 139 | $47.89 |
| 87077 | <1% | 27 | $46.32 | |
| 87040 | <1% | 87 | $44.61 | |
| 85379 | <1% | 38 | $19.44 | |
| 85730 | <1% | 37 | $17.19 | |
| 82550 | <1% | 45 | $13.17 | |
| 81000 | <1% | 17 | $9.06 | |
| 87205 | <1% | 12 | $4.07 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 376 | $2.27 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 34 | $0.00 |
| 96376 | 0% | 152 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 118 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 59 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 14 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 93 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 38 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 43 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 12 | $0.00 |
| 86901 | 0% | 18 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 55 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 14 | $0.00 |
| 86850 | 0% | 18 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 300 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 725 | $0.00 |
| 87631 | 0% | 15 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRINN, JACQUELINE (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Yale New Haven Hospital | New Haven, CT | $1.08B |
| Bridgeport Hospital | Bridgeport, CT | $287.34M |
| Lawrence and Memorial Hospital, INC. | New London, CT | $136.19M |
| Greenwich Hospital | Greenwich, CT | $46.42M |
| Bridgeport Hospital | Milford, CT | $15.60M |
| Lawrence and Memorial Hospital, INC. | New London, CT | $1.55M |
| Yale New Haven Hospital | New Haven, CT | $629K |
| LMW Healthcare INC. | Westerly, RI | $492K |
| Bridgeport Hospital | Bridgeport, CT | $398K |
| Lawrence and Memorial Hospital, INC. | New London, CT | $365K |
| Shoreline Endoscopy Center, LLC | Guilford, CT | $19K |
| Yale New Haven Hospital | New Haven, CT | $860.83 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.